Jazz Pharmaceuticals completes $820M acquisition of Actio Biosciences
Jazz Pharmaceuticals closed its acquisition of privately held Actio Biosciences for $820 million upfront, adding KCNT1-related epilepsy candidate ABS-1230.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.